林招煌’s Post

Here's an update on the biosimilar promotion by our government.

Revised Roadmap for the Use of Generic Drugs in Japan The Ministry of Health, Labour and Welfare (MHLW) has set new targets in its updated roadmap for generic and biosimilar usage. The main goal remains to ensure a stable supply of pharmaceuticals while increasing the share of generics across all prefectures. Key Objectives: Main Goal: By the end of FY2029, the quantity share of generic drugs in every prefecture will exceed 80%. Sub-goal 1: At least 60% of active ingredients will see biosimilar penetration of 80% or more by FY2029. Sub-goal 2: By FY2029, the value share of generics will exceed 65%. These efforts are crucial in maintaining public trust and ensuring a stable pharmaceutical supply. By meeting these targets, we aim to balance cost-efficiency with the continuous availability of high-quality medicines. https://lnkd.in/gN9eTQid #pharmaceuticals #generics #biosimilars #healthcareinnovation #japanhealthcare

🖥💊 製薬会社では、痛みの緩和や治癒が証明された新薬が市場に出ると、最高の品質と純度で迅速に大量生産をする必要があります。Pepperl+FuchsのHMIシステムは、医薬品の大規模生産に携わるスタッフが常にすべての情報を把握し、作業を文書化できるようにするために、使用されています。 When new medicines come onto the market that promise relief or even a cure, large quantities have to be produced quickly—in the highest quality and purity. Weight loss injections for the treatment of obesity are the latest example of such a breakthrough. HMI systems such as those from Pepperl+Fuchs are used to ensure that personnel in the large-scale production of pharmaceuticals always have an overview of all information and can document work steps. どのHMIシステムが使用されているのか？ Which HMI systems are used for this task? Amplifyへ(英語): https://lnkd.in/e-5fFrtB #AutomationPassion #HMI #PharmaceuticalIndustry

Peter Lee, CEO of Biocell Lab, visited Hinan Haiping International Medical Device Industrial Park (HP) to sign the MOU. Two other renowned Korean filler companies have already established their presence there, and we are proud to become the third to set up manufacturing facilities following the establishment of our joint venture. This marks a significant achievement for Biocell Lab as we solidify our position as a major industry player, bringing advanced Korean technology to manufacture fillers for the Chinese market.

Today CN Bio announced a strategic partnership with Primetech Corporation to establish a distribution channel for the company’s organ-on-a-chip (OOC) solutions in Japan. This agreement will provide local support and expertise to CN Bio’s Japanese customers and solidifies the Company’s presence in Asian markets, supporting its ongoing global expansion. Read the full press release here: https://bit.ly/4heg3VM

According to a recent announcement from the University at Buffalo, Merck & Co., Inc. has acquired the biotechnology startup Abceutics Inc., for US$208 million. The deal includes milestone payments based on the developmental achievements of the pipeline as outlined in their contract. Industry insiders have noted that we may see increased M&As among biotech firms in the future, seeking to capitalize on complementary strengths and consolidate resources for mutual benefit. "Historical data indicates that about one-third of global innovative drug revenues come from products developed through in-house R&D, with the remaining two-thirds arising from acquisitions and collaborations (including licensing)," Jin Wang, Senior Partner at McKinsey & Company, told our reporter in an exclusive interview. "For the top 20 multinational pharmaceutical companies, an average of 55% of their products in clinical stages originate from in-house R&D, while 45% result from external innovation. However, some firms rely much more heavily on external sources, with dependencies rangling from 60% to 70%." Read: https://lnkd.in/gZir2Ya5

To stay competitive and innovative, #MedTech companies face increasing pressure to optimize R&D operations while ensuring safety, efficacy, and regulatory compliance. Enter Contract Research Organizations (#CROs)—a solution to reduce costs, enhance scalability, and speed up time-to-market without compromising quality. Explore the benefits of partnering with CROs and the key factors to consider: https://bit.ly/3APjAKu

COVALENT INHIBITORS: OVER A CENTURY OF HISTORY! Excellent and efficient approach in medicinal chemistry for effectiveness, selectivity and long-lasting effect. Covalent inhibitors provide persistent inhibition while maintaining excellent selectivity and efficacy by creating stable covalent connections with specific amino acids in target proteins. This technique enables the precise inhibition of previously undruggable targets, lowering the frequency of administration and potentially bypassing drug resistance. Because of these advantages, covalent inhibitors have tremendous potential in treating cancer, inflammation, and infectious illnesses, making them extremely important in modern pharmacological research. Covalent inhibitors targeting EGFR, BTK, and KRAS (G12X), which overcome drug resistance and off-target, non-"medicinal" difficulties, as well as covalent inhibitors targeting SARS-CoV-2 Mpro, have paved the way for the development of new antiviral medicines. Furthermore, the use of covalent methods in drug discovery procedures, such as covalent PROTACs, covalent molecular gels, covalent probes, CoLDR, and Dual-targeted covalent inhibitors, preserves these tactics' inherent features while incorporating the advantages of covalent inhibitors. This synthesis opens up new therapeutic opportunities. This review comprehensively examines the use of covalent techniques in drug discovery, emphasizing their transformational potential for future drug development. #CovalentInhibitors https://lnkd.in/drz4k_DN

By establishing a one-step continuous flow synthesis method using inexpensive raw materials and fluorine gas, a low-cost manufacturing process was developed to meet the WHO's demand for flucytosine supply. https://lnkd.in/gyBe-VAY #chemistry #pharmaceutical #process

Learn how micronization is a well-established, cost-effective and scalable process to address bioavailability and drug delivery challenges facing certain HPAPIs. https://ow.ly/r8rY50TgM67